{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-016726","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.016719+00:00","generated_at":"2026-06-06T16:36:11.447136+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Homology Medicines furnishes Q32 Bio investor presentation for proposed merger; cash runway into mid-2026","bullets":["Presentation highlights Q32's pipeline: bempikibart (phase 2 for alopecia areata/atopic dermatitis) and ADX-097 (phase 1/2 for complement-mediated diseases).","Combined company expects cash, cash equivalents and short-term investments to fund operations into mid-2026.","Merger expected to close in Q1 2024, subject to Homology stockholder approval and other customary conditions.","CVRs may provide contingent payments to Q32 stockholders based on future milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-016726","json":"https://secwatch.observer/filing/0001193125-24-016726.json","markdown":"https://secwatch.observer/filing/0001193125-24-016726.md","text":"https://secwatch.observer/filing/0001193125-24-016726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524016726/0001193125-24-016726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524016726/d736571d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T16:36:11.447136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}